Literature DB >> 12172459

Clinical application of the PFA-100.

Emmanuel J Favaloro1.   

Abstract

The PFA-100 (platelet function analyzer) is a relatively new tool for the investigation of primary hemostasis. Recent studies have shown its utility as a screening tool for investigating possible von Willebrand disorder (VWD) and various platelet disorders. More recently, the PFA-100 has been shown to be valuable in monitoring desmopressin acetate (DDAVP) therapy in both VWD and platelet disorders. The PFA-100 has also been evaluated in many other studies for its utility in assessing drug effects, for potential monitoring of antiplatelet medication (including aspirin), or for evaluation of overall primary hemostasis in various clinical disorders or during surgical procedures. This article reviews current findings and highlights the benefits and limitations of the clinical utility of the PFA-100. Ultimately, the greatest strengths of the PFA-100 are its simplicity of use and excellent sensitivity to particular hemostatic disturbances such as VWD, platelet disorders, and platelet-affecting medication. However, because it is thus a global test system, this also creates a significant limitation because the PFA-100 is not specific for, nor predictive of, any particular disorder. However, used appropriately, the PFA-100 can be considered a worthwhile addition to any hemostasis laboratory involved in the diagnosis or therapeutic monitoring of bleeding disorders and potentially of antiplatelet medication. This review should be valuable to both hemostasis scientists and clinical specialists. Copyright 2002 Lippincott Williams & Wilkens, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12172459     DOI: 10.1097/00062752-200209000-00004

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  20 in total

1.  Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.

Authors:  Takahide Arai; Akio Kawamura; Yumiko Matsubara; Kenji Yokoyama; Yasuo Ikeda; Keiichi Fukuda; Mitsuru Murata
Journal:  Heart Vessels       Date:  2011-08-12       Impact factor: 2.037

2.  The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

Authors:  Burak Pamukcu; Huseyin Oflaz; Rezzan Deniz Acar; Sabahattin Umman; Nevres Koylan; Berrin Umman; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

3.  Coagulation parameters and platelet function analysis in patients with acromegaly.

Authors:  A Colak; H Yılmaz; Y Temel; M Demirpence; N Simsek; İ Karademirci; U Bozkurt; E Yasar
Journal:  J Endocrinol Invest       Date:  2015-06-06       Impact factor: 4.256

4.  Can resistance to aspirin be reversed after an additional dose?

Authors:  David Vivas; Esther Bernardo; Juan Carlos García-Rubira; Luis Azcona; Ivan Núñez-Gil; Juan Jose González-Ferrer; Carlos Macaya; Dominick J Angiolillo; Antonio Fernández-Ortiz
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

5.  Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.

Authors:  Tyler J Gluckman; Rhondalyn C McLean; Steven P Schulman; Thomas S Kickler; Edward P Shapiro; John V Conte; Kathleen W McNicholas; Jodi B Segal; Jeffrey J Rade
Journal:  J Am Coll Cardiol       Date:  2011-03-01       Impact factor: 24.094

6.  Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.

Authors:  I L Meek; H E Vonkeman; J Kasemier; K L L Movig; M A F J van de Laar
Journal:  Eur J Clin Pharmacol       Date:  2012-08-14       Impact factor: 2.953

7.  Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress.

Authors:  Leonard C Edelstein; Elizabeth J Luna; Ian B Gibson; Molly Bray; Ying Jin; Altaf Kondkar; Srikanth Nagalla; Nacima Hadjout-Rabi; Tara C Smith; Daniel Covarrubias; Stephen N Jones; Firdos Ahmad; Moritz Stolla; Xianguo Kong; Zhiyou Fang; Wolfgang Bergmeier; Chad Shaw; Suzanne M Leal; Paul F Bray
Journal:  Circulation       Date:  2012-05-01       Impact factor: 29.690

8.  Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.

Authors:  Oyku Gulmez; Aylin Yildirir; Gamze Kaynar; Didem Konas; Alp Aydinalp; Cagatay Ertan; Bulent Ozin; Haldun Muderrisoglu
Journal:  J Thromb Thrombolysis       Date:  2007-06-16       Impact factor: 2.300

Review 9.  Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.

Authors:  Rakesh K Sharma; Hanumanth K Reddy; Vibhuti N Singh; Rohit Sharma; Donald J Voelker; Girish Bhatt
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

10.  Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy.

Authors:  Susanna M Nazarian; Jason B Thompson; Tyler J Gluckman; Katherine Laws; Jayesh T Jani; Thomas S Kickler; Jeffrey J Rade
Journal:  Thromb Res       Date:  2009-06-05       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.